Bactroban Related Published Studies
Well-designed clinical trials related to Bactroban (Mupirocin Topical)
Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. [2008.09]
A RANDOMIZED CONTROLLED TRIAL COMPARING MUPIROCIN VERSUS POLYSPORIN TRIPLEa FOR THE PREVENTION OF CATHETER-RELATED INFECTIONS IN PERITONEAL DIALYSIS PATIENTS (THE MP3 STUDY). [2008.01]
Targeted Intranasal Mupirocin To Prevent Colonization and Infection by Community-Associated Methicillin-Resistant Staphylococcus aureus Strains in Soldiers: a Cluster Randomized Controlled Trial. [2007.10]
Prophylactic intranasal mupirocin ointment in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients. [2007.03]
Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. [2007.01.15]
Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. [2005.05]
Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. [2004.03.16]
A prospective, randomized pilot evaluation of topical triple antibiotic versus mupirocin for the prevention of uncomplicated soft tissue wound infection. [2004.01]
The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience. [2004]
Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. [2003.12.01]
Randomized clinical trial of preoperative intranasal mupirocin to reduce surgical-site infection after digestive surgery. [2003.09]
The preventive effects of mupirocin against nasotracheal intubation-related bacterial carriage. [2003.07]
[Use of nasal mupirocin for Staphylococcus aureus: effect on nasal carriers and nosocomial infections] [2003.06]
A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. [2002.10]
Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. [2002.08.15]
Mupirocin vs terbinafine in impetigo. [2002.08]
Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. [2002.06.13]
A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. [2002.01]
Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin. [2001.09]
A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. [1999.09]
Perianal candidosis--a comparative study with mupirocin and nystatin. [1999.08]
Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. [1999.06]
Bacitracin versus mupirocin for Staphylococcus aureus nasal colonization. [1999.05]
[Endonasal mupirocin in the prevention of nosocomial pneumonia] [1999.03]
Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial. [1999.01]
Mupirocin cream is as effective as oral cephalexin in the treatment of secondarily infected wounds. [1998.12]
Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. [1998.06]
A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. [1996.05.27]
A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. [1996.05]
A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. [1995.03]
Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. [1995.01]
Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. [1994.07.11]
Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. [1993.09]
Treatment of familial staphylococcal infection--comparison of mupirocin nasal ointment and chlorhexidine/neomycin (Naseptin) cream in eradication of nasal carriage. [1993.06]
Staphylococcus aureus and intra-nasal mupirocin in patients receiving isotretinoin for acne. [1992.04]
Mupirocin treatment of nasal staphylococcal colonization. [1992.02]
Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children. [1992.02]
Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. [1992.02]
Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. [1992]
Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. [1991.01.15]
Use of mupirocin ointment in the treatment of secondarily infected dermatoses. [1990.05]
A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. [1990.05]
Mupirocin for the reduction of colonization of internal jugular cannulae--a randomized controlled trial. [1990.05]
Effect of mupirocin on nasal carriage of Staphylococcus aureus. [1989.08]
Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. [1989.08]
Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. [1989.06]
Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin. [1989.06]
Topical antibiotics in the treatment of superficial skin infections in general practice--a comparison of mupirocin with sodium fusidate. [1989.05]
Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. [1988.12]
Topical mupirocin vs. systemic erythromycin treatment for pyoderma. [1988.11]
Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. [1988.08]
[Comparative double-blind evaluation of a new topical antibacterial agent, mupirocin, compared with placebo in the treatment of skin and soft tissue infections] [1988]
Well-designed clinical trials possibly related to Bactroban (Mupirocin Topical)
The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. [2009.05]
Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. [2009.05]
Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. [2008.05]
Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: Diagnosis and treatment. [2008.03]
Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. [2007.09]
Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. [2006.10]
Impact of treating Staphylococcus aureus nasal carriers on wound infections in cardiac surgery. [2006.10]
Randomized clinical trial of the effect of applying ointment to surgical wounds before occlusive dressing. [2006.08]
Prevention of acquired infections in intubated patients with the combination of two decontamination regimens. [2005.02]
Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. [2005.02]
[Perioperative nosocomial infection preventive measures] [2004.11]
A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. [2004.04]
Prevention of Staphylococcus aureus infections among surgical patients: beyond traditional perioperative prophylaxis. [2003.11]
Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. [2000.12]
The treatment of Staphyloccocus aureus infected sore nipples: a randomized comparative study. [1999.09]
Eradication of nasal carriage of Staphylococcus aureus--is it cost-effective? [1998.09]
Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. [1996.12]
Nasal and hand carriage of Staphylococcus aureus in healthcare workers. [1994.04]
Other research related to Bactroban (Mupirocin Topical)
Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. [2009.08.13]
Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. [2009.07]
Phenotypic and molecular characterization of Staphylococcus aureus isolates expressing low- and high-level mupirocin resistance in Nigeria and South Africa. [2009.01.28]
Development of microsponges for topical delivery of mupirocin. [2009]
Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. [2008.10.08]
Prevention of staphylococcal peritonitis in CAPD patients combining ablution and mupirocin. [2008.09]
A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections. [2008.09]
Prevention of Staphylococcus aureus burn wound colonization by nasal mupirocin. [2008.09]
Clinical Effectiveness of Ototopical Application of Mupirocin Ointment in Methicillin-Resistant Staphylococcus aureus Otorrhea. [2008.08]
Efficacy of nasal Staphylococcus aureus eradication by topical nasal mupirocin in patients with perennial allergic rhinitis. [2008.06]
In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. [2008.03]
A comparison of the prophylactic uses of topical mupirocin and nitrofurazone in murine crush contaminated wounds. [2008.02]
Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. [2008.02]
Intranasal mupirocin prophylaxis in elective surgery. A review of published studies. [2008]
Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience. [2008]
Does nasal colonization or mupirocin treatment affect recurrence of methicillin-resistant Staphylococcus aureus skin and skin structure infections? [2007.12]
Risk Factors for Methicillin-Resistant Staphylococcus aureus (MRSA) and Use of a Nasal Mupirocin Ointment in Oral Cancer Inpatients. [2007.11]
Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. [2007.10]
Antibacterial activity of propolis against MRSA and synergism with topical mupirocin. [2007.09]
Direct economic effect following mupirocin therapy failure among patients with uncomplicated skin and skin-structure infections in a large population-based cohort. [2007.07]
Risk factors for isolation of low-level mupirocin-resistant versus -susceptible methicillin-resistant Staphylococcus aureus from patients in intensive care units. [2007.04]
Interpretive criteria for mupirocin susceptibility testing of Staphylococcus spp. using CLSI guidelines. [2007]
REDUCTION OF PREOPERATIVE CONJUNCTIVAL BACTERIAL FLORA WITH THE USE OF MUPIROCIN NASAL OINTMENT. [2006.12]
Preoperative use of mupirocin for the prevention of healthcare-associated Staphylococcus aureus infections: a cost-effectiveness analysis. [2006.12]
Impact of prophylactic mupirocin for radical esophagectomy. [2006.10]
Long-term efficacy of mupirocin in the prevention of infections with meticillin-resistant Staphylococcus aureus in a gastroenterology unit. [2006.08]
Safety of targeted perioperative mupirocin treatment for preventing infections after cardiac surgery. [2006.06]
Treatment of chronic rhinosinusitis exacerbations due to methicillin-resistant Staphylococcus aureus with mupirocin irrigations. [2006.05]
Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin. [2006.03]
Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. [2006.02]
Controlling the usage of intranasal mupirocin does impact the rate of Staphylococcus aureus deep sternal wound infections in cardiac surgery patients. [2006.02]
|
